Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Mesothelioma; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 May 2017 Status changed from active, no longer recruiting to completed.
- 24 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.